Company: BDRX
Filing Date: 2025-05-08
Form Type: POS AM
Source: 0001214659-25-007201
Chunk: 14

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-05-08
Form: POS AM
Chunk 14
---
you that there are some known and unknown factors that could cause actual results to differ materially from any future results, performance
or achievements expressed or implied by such forward-looking statements, including but not limited to risks related to:

| · | our requirement for additional financing and our ability to continue as a going concern; |

| · | our estimates regarding losses, expenses, future revenues, capital requirements and needs for additional 
 financing;                                                                                               |

| · | our ability to successfully develop, test and partner with a licensee to manufacture or commercialize 
 products for conditions using our technology platforms;                                               |

| · | the successful commercialization and manufacturing of our any future product we may commercialize or license; |

| · | the success and timing of our preclinical studies and clinical trials; |

| · | shifts in our business and commercial strategy; |

| · | the filing and timing of regulatory filings, including Investigational New Drug applications, with respect to any of our product candidates 
 and the receipt of any regulatory approvals;                                                                                                |

| · | the anticipated medical benefits of our product candidates; |

| · | the difficulties in obtaining and maintaining regulatory approval of our product candidates, and the labeling 
 under any approval we may obtain;                                                                             |

| · | the success and timing of the potential commercial development of our product candidates and any product 
 candidates we may acquire in the future, including eRapa, tolimidone and MTX110;                         |

| · | our plans and ability to develop and commercialize our product candidates and any product candidates we 
 may acquire in the future;                                                                              |

| · | the ability to manufacture products in third-party facilities; |

| · | the rate and degree of market acceptance of any of our product candidates; |

| 10 |

| · | the successful development of our commercialization capabilities, including our internal sales and marketing 
 capabilities;                                                                                                |

| · | obtaining and maintaining intellectual property protection for our product candidates and our proprietary 
 technology;                                                                                               |

| · | the success of competing therapies and products that are or become available; |

| · | the success of any future acquisitions or other strategic transactions; |

| · | the difficulties of integrating the business of any future acquisitions into our own; |

| · | cybersecurity and other cyber incidents; |

| · | industry trends; |

| · | the impact of government laws and regulations; |

| · | regulatory, economic and political developments in the United Kingdom, the European Union, the United        
 States and other foreign countries, including any impact